Market Overview

UPDATE: Deutsche Bank Raises PT to $115 on Perrigo Post Rosemont Acquisition

Related PRGO
Worst Performing Industries For December 23, 2014
Top Performing Industries For November 24, 2014
Horizon Inks $660M Reverse Merger With Ireland's Vidara (Fox Business)

Deutsche Bank maintained Perrigo (NASDAQ: PRGO) with a Hold rating and raised the price target from $110.00 to $115.00.

Deutsche Bank noted, "Perrigo announced on Monday the acquisition of UK-based Rosemont Pharmaceuticals for £180M or USD $283M in cash. … Rosemont appears to be a well diversified business, with 2012 sales of £40M (approx $60M, growing mid to high single digit over a number of years) from over 90 products – none more than 8% of revenue. This acquisition on the surface, however, looks a little expensive on a revenue multiple basis – at approximately 4.5x sales vs typical generic acquisition multiples of approximately 2.8x sales in recent years. That said, niche acquisitions in the generic injectables segment have garnered an average revenue multiple of 4.5x."

Perrigo closed at $111.40 on Monday.

Latest Ratings for PRGO

DateFirmActionFromTo
Nov 2014CRT CapitalMaintainsBuy
Nov 2014CRT CapitalReiteratesBuy
Aug 2014JefferiesMaintainsBuy

View More Analyst Ratings for PRGO
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings

 

Related Articles (PRGO)

Around the Web, We're Loving...

Get Benzinga's Newsletters